Sarepta Therapeutics (NASDAQ:SRPT) reported a second fatality from acute liver failure in a patient treated with its gene ...

Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.

U.S. stock futures are pointing higher as investors monitor geopolitical tensions ahead of a holiday-shortened week; Victoria's Secret shares are rising in premarket trading on a ...

Investors are regaining some appetite for risk amid rising optimism that the conflict won't spill over into a broader ...

Ongoing fighting in the Middle East wasn't enough to dampen European stocks on Monday, as investors stepped in to snap up bargains after markets hit a one-month low the previous session.

Sarepta’s shares crashed 41% in pre-market trading Monday morning to $21.01 after the biotech reported a second death from ...